

MAY 10 2002

RECEIVED  
Sheet 1 of 2

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09531-088001	Application No. 10/033,577
	Applicant Daniel Vallera, et al.		TECH CENTER 1600/2900
	Filing Date December 28, 2001	Group Art Unit 1645	

## U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KAC	AA	4,340,535	07/20/82	Voisin et al.			
	AB	4,545,985	10/08/85	Pastan et al.			
	AC	4,675,382	06/23/87	Murphy			
	AD	4,831,112	05/16/89	Kobayashi et al.			
	AE	5,208,021	05/04/93	Johnson et al.			
	AF	5,709,843	01/20/98	Reisner			
	AG	5,720,720	02/24/98	Laske et al.			
	AH	5,728,383	03/17/98	Johnson et al.			
	AI	5,792,458	08/11/98	Johnson et al.			
	AJ	5,894,018	04/13/99	Davila et al.			
✓	AK	6,001,329	12/14/99	Buchsbaum et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
KAC	AM	✓ GenBank Accession No. E01560
	AN	✓ GenBank Accession No. K01722
	AO	✓ Collier and Kandel, "Structure and Activity of Diphtheria Toxin," <u>J. Biol. Chem.</u> , 1971, 246(5):1496-1503
	AP	✓ Collier, "Structure and Activity of Diphtheria Toxin," <u>ADP-Ribosylation Reactions - Biology and Medicine</u> , 1982, Academic Press, New York, Chapter 34, pp. 575-592
	AQ	✓ Davis et al., "Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991," <u>J. Neurosurg.</u> , 1998, 88:1-10
	AR	✓ Fabbrini et al., "The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated," <u>FASEB J.</u> , 1997, 11:1169-1176
	AS	✓ Greenfield et al., "Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage β," <u>Proc. Natl. Acad. Sci. USA</u> , 1983, 80:6853-6857
✓	AT	✓ Kreitman, "Immunotoxins in cancer therapy," <u>Curr. Opin. Immunol.</u> , 1999, 11:570-578

Examiner Signature

Karen J. Gamella

Date Considered

5/27/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4

MAY 10 2002

RECEIVED  
Sheet 2 of 2Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
09531-088001Application No. 5 2002  
10/033,577**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Daniel Vallera, et al.

TECH CENTER 1600/2900

Filing Date  
December 28, 2001Group Art Unit  
1645**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
KAC	AU	Laske et al., "Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors," <u>Nature Medicine</u> , 1997, 3(12):1362-1368
	AV	Marshall, "A New Phase in the War on Cancer," <u>Science</u> , 1995, 267:1412-1415
	AW	McKeever, "Insights About Brain Tumors Gained Through Immunohistochemistry and in Situ Hybridization of Nuclear and Phenotypic Markers," <u>J. Histochem. Cytochem.</u> , 1998, 46(5):585-594
	AX	Mori et al., "Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor- $\alpha$ or basic fibroblast growth factor," <u>J. Neuro-Oncology</u> , 2000, 46:115-123
	AY	Moskaug et al., "Translocation of Diphtheria Toxin A-fragment to the Cytosol," <u>J. Biol. Chem.</u> , 1989, 264(26):15709-15713
	AZ	Oldfield and Youle, "Immunotoxins for Brain Tumor Therapy," <u>Current Topics in Microbiology and Immunology</u> , 1998, 234:97-114
	AAA	Pastan and FitzGerald, "Pseudomonas Exotoxin: Chimeric Toxins," <u>J. Biol. Chem.</u> , 1989, 264(26):15157-15160
	ABB	Rajagopal and Kreitman, "Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the $\alpha_2$ -Macroglobulin Receptor," <u>J. Biol. Chem.</u> , 2000, 275(11):7566-7573
	ACC	Ramakrishnan et al., "Vascular Endothelial Growth Factor-Toxin Conjugate Specifically Inhibits KDR/flk-1-positive Endothelial Cell Proliferation <i>in Vitro</i> and Angiogenesis <i>in Vivo</i> ," <u>Cancer Res.</u> , 1996, 56:1324-1330
	ADD	Vallera et al., "Anti-Graft-Versus-Host Disease Effect of DT <sub>390</sub> -Anti-CD3sFv, a Single-Chain Fv Fusion Immunotoxin Specifically Targeting the CD3 $\epsilon$ Moiety of the T-Cell Receptor," <u>Blood</u> , 1996, 88(6):2342-2353
	AEE	Vallera et al., "Renal dysfunction accounts for the dose limiting toxicity of DT <sub>390</sub> anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin," <u>Protein Engin.</u> , 1997, 10(9):1071-1076
	AFF	Vallera et al., "Retroviral Immunotoxin Gene Therapy of Acute Myelogenous Leukemia in Mice Using Cytotoxic T Cells Transduced with an Interleukin 4/Diphtheria Toxin Gene," <u>Cancer Res.</u> , 2000, 60:976-984

Examiner Signature

Karen A. Camilleri

Date Considered

5/27/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)